Abbvie Inc., et al. v. Mylan Pharmaceuticals Inc., et al., C.A. No. 13-1072 – RGA, June 3, 2015
Andrews, J. Claim construction opinion regarding x disputed terms from 6 patents. Oral argument took place on May 22, 2015.
The disputed product relates to ritanovir. The disputed claims construed are:
-
Formulated as a solid dispersion of amorphous ritonavir in a matrix including a water soluble polymer
-
Solid dispersion
-
Solid solution
-
Molecular dispersion
-
Self-emulsifying
-
Composition